Collaboration Opportunities

Supporting Research into Sepsis and Inflammatory Disorders

We believe that collaboration is the key to advancing medical innovation and improving global health outcomes. We welcome researchers and commercial organisations who are interested in applications for our 10-minute sepsis point-of-care (POC) test, and our proprietary portfolio of anti-human soluble Toll-like Receptor 2 (sTLR2) monoclonal and polyclonal antibodies. UK Patent Application GB2502531.3.

The IMIWN sTLR2 Rapid test is currently UKCA certified in Great Britain, and available elsewhere for research use. To discuss licensing opportunities for our panel of monoclonal and polyclonal antibodies for research and commercial use, or distribution of our antibodies, reagents and diagnostics, please contact us.

Opportunities Offered

We invite researchers, pharmaceutical companies and medical diagnostic corporations to partner with us.

IMIWN sTLR2 Sepsis POC Test

  • Scientific Research: Scientific and clinical research of sTLR2 in health and disease
  • Contract Research: CRO services to accelerate your research by using our laboratory and expertise to measure your patient samples with our sTLR2 RAPID and ELISA diagnostics
  • Distribution Agreements: Leverage your established sales channels and market expertise to bring our sepsis POC test to clinicians and laboratories
  • Co-Development Partnerships: Collaborate on further enhancements, next-generation products, or specific market adaptations

IMIWN sTLR2 Antibody Portfolio

  • Scientific Research: Potential applications include Western Blotting, flow cytometery, histology, ELISA, therapeutics
  • Licensing for Diagnostic Kit Manufacturing: Integrate our monoclonal and polyclonal sTLR2 antibodies into your IVD products
  • Bulk Supply & OEM Agreements: Ensure a consistent and reliable supply of sTLR2 antibodies for research, reagent or manufacturing needs
  • Co-Development for New Applications: Partner with us to explore and develop new diagnostic or research applications based on our sTLR2 antibodies

We are keen to collaborate with organisations that share our vision and possess complementary strengths. We are particularly interested in partnering with:

  • Clinical and scientific immunologists
  • Pharmaceutical companies seeking to expand their diagnostic portfolios or find companion diagnostics
  • Medical diagnostic companies with established global or regional market presence, strong sales and marketing capabilities, and expertise in IVD commercialization
  • Companies with expertise in global regulatory affairs (FDA, CE-IVDR), point-of-care test distribution, distributors in the inflammation and critical care markets

Let's Connect

If you are at the forefront of sepsis diagnostics or inflammatory biomarker research and innovation, we invite you to connect with our team. Let's discuss how our technologies can align with your goals in improving patient care.

Contact our team today through our contact form, or email help@jrbiomed.com